---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-068007"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:27:47.563284+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Brainstorm Cell Therapeutics temporary exception until Oct 21 for bid price compliance

## Summary
- Company received delisting notice on May 1 for failing $1 minimum bid price; appealed on May 2.
- Nasdaq granted temporary exception until Oct 21, 2024; must comply by then or face delisting.
- If not compliant by mid-August 2024, must execute reverse stock split no later than Oct 7, 2024.
- No assurance reverse split will achieve compliance; delisting risk persists if deadline missed.

## SEC filing metadata
- accession: 0001104659-24-068007
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465924068007/0001104659-24-068007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465924068007/tm2416355d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-068007
- JSON: https://secwatch.observer/filing/0001104659-24-068007.json
- Plain text: https://secwatch.observer/filing/0001104659-24-068007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.